Overview

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

Status:
Suspended
Trial end date:
2022-05-27
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19
Phase:
Phase 4
Details
Lead Sponsor:
Providence Health & Services
Collaborators:
Center for Outcomes Research and Education
Providence Cancer Center, Earle A. Chiles Research Institute
Treatments:
Ascorbic Acid
Hydroxychloroquine
Vitamins